MBMurat Bazarov

Murat Bazarov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Murat Bazarov has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    INTRA-ARTICULAR ADMINISTRATION OF AUTOLOGOUS AND ALLOGENEIC MESENCHYMAL STROMAL CELLS FOR KNEE OSTEOARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL STUDIES

    by Olexandr Burianov, Taras Omelchenko, Yuriy Sobolevskiy, Maksym Zahorodnyi, Murat Bazarov, Liudmyla Khimion

    Objective. To evaluate the efficacy and safety of intra-articular administration of autologous and allogeneic mesenchymal stromal cells in the treatment of knee osteoarthritis based on a systematic review and meta-analysis of clinical studies. Methods. A systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 principles. The literature search was performed in PubMed, Scopus, Web of Science, and Cochrane Library databases for the period from 2010 to 2025. The qualitative analysis included 11 clinical studies evaluating the efficacy and/or safety of intra-articular mesenchymal stromal cell administration in patients with knee osteoarthritis. Results. The VAS meta-analysis included 4 controlled studies with a total of 87 participants, while the WOMAC metaanalysis included 3 controlled studies with a total of 67 participants. Intra-articular administration of mesenchymal stromal cells was associated with a statistically significant reduction in pain intensity according to the VAS score: SMD = −1.09; 95 % CI: −1.81 to −0.36; p = 0.003; I² = 56 %. A statistically significant improvement in functional status according to the WOMAC score was also observed: S MD = −0.62; 95 % CI: −1.19 to −0.05; p = 0.03; I ² = 22 %. In most included studies, mesenchymal stromal cell therapy was well tolerated. The most commonly reported adverse events were transient local pain, swelling, or mild synovitis after injection. Conclusions. Intra-articular administration of mesenchymal stromal cells may represent a promising biological approach for the treatment of knee osteoarthritis, as it is associated with pain reduction and functional improvement.

  • Open Access

    Bone marrow mesenchymal stem cells in the treatment of patients with knee osteoarthritis

    by O.A. Burianov, T.M. Omelchenko, L.V. Khimion, M.O. Bazarov, O.A. Turchin, Ye.A. Levitskiy, Yu.L. Sobolevskiy

    Background. The use of mesenchymal stem cells (MSCs) in joint lesions is an extremely controversial issue due to the presence of numerous unresolved problems both in understanding the biological properties of MSCs and in terms of their practical application. The purpose of the study was to evaluate the functional results and clinical efficacy of using autologous MSCs obtained from bone marrow in the treatment of patients with post-traumatic osteoarthritis (PTOA) of the knee joint (KS) in the early stages, during a six-month observation period. Materials and methods. 28 patients with PTOA of the knee joint of stage I–II according to Kellgren-Lawrence were treated. Among them, 11 (39.0 %) were men and 17 (61.0 %) were women, the average age was 44.80 ± 10.95 years. The average period after the injury was 7.8 ± 0.5 years. MSCs were harvested from the iliac wing and cultured in a biotechnology laboratory. Intra-articular injection was performed once during exacerbation of PTOA (50 million cells). Efficacy was assessed after 6 months. Evaluation criteria: need for NSAIDs, number of exacerbations of PTOA; functional status of the joint according to Lisholm and WOMAC. Pain syndrome was assessed using the visual analog scale (VAS), quality of life according to the 36-Item Short Form Survey (SF-36) scale. Results. After 6 months after the use of MSC, positive dynamics were obtained in all categories of assessment of the functional status of the knee joint: pain according to VAS decreased to 2.2 ± 0.3 (p < 0.05); functional activity according to the Lisholm scale increased by 29.4 % (p < 0.01), the total WOMAC index decreased by 51.7 % (p < 0.01); the quality of life index increased by 57.7 ± 9.3 % when assessed using ­SF-36 (p < 0.01). In addition, during the 6-month clinical observation period following the use of MSCs, a significant decrease in the frequency of exacerbations of PTOA compared to the previous 6-month period and a decrease in the need for NSAIDs were demonstrated. Conclusion. MSCs are an effective and safe method of treating PTOA of the knee in the early stages, accompanied by a significant decrease in pain syndrome indicators, improvement in joint function and quality of life, as well as a decrease in the number of PTOA exacerbations and the need for NSAIDs for at least 6 months.

  • Open Access

    Use of scaffolds based on polyetheretherketone tubular implant in the treatment of a gunshot multifragmentary fracture of the proximal part of the shoulder with a bone defect: a case report

    by Oleksandr Buryanov, Igor Lurin, Bazarov Murat, Yurii Yarmoliuk, Artem Bespalenko, Oleg Smyk, Yurii Klapchuk, Dmytro Los

    In connection with the war in Ukraine and the use of modern high-energy weapons by the enemy, the nature of injuries have changed. These changes require improvement of approaches to the treatment of patients with gunshot and mine-explosive bone defects. We present the case of treatment of a 28-year-old Ukranian man with a gunshot multifragmentary fracture of the proximal humerus with a bone defect using three-dimensional printing of a polyetheretherketone frame (scaffold) for alloplastic material. The analysis of this case expands the possibilities of using three-dimensional printing technologies of polyetheretherketone scaffolds in the treatment of significant bone defects. Modern military trauma requires individualized treatment for each patient. The use of individual polyetheretherketone scaffolds in the treatment of a gunshot multifragmentary fracture with a bone defect has a positive clinical effect.


  • Reconstructive surgery for gunshot injuries of the knee: experience from the Russo-Ukranian War 2022–2024

    by Yurii Klapchuk, D Los, O Buryanov, Y Yarmoliuk, M Bazarov, I Bets, V Lyanskorunsky, B Vashkevych, A Ramasamy

    The invasion of Ukraine by the Russian Federation in February 2022 has witnessed the first peer-on-peer full-scale European conflict since World War 2. We have noted that the vast majority of injuries affect the extremities. Within that group, injuries to the joints pose a huge clinical challenge. Specifically, 17.1% of all gunshot injuries (GSWs) involved the joints, which represents 22.3% of all limb injuries. 55.6% of all GSW to the joints involved the knee; 10% had a concomitant vascular injury and 15%–20% had a nerve injury. The surgical management of ballistic knee injuries includes initial damage control surgery with debridement of non-vitalised tissue, vascular reconstruction and fasciotomies where necessary, with stabilisation of bone injury with a spanning external fixator. Following repatriation to Role 4 facilities, staged reconstruction is performed with cement spacers followed by autograft, endoprosthesis or arthrodesis. Where reconstruction is not possible, above-knee amputation remains an option. In this paper, based on the analysis of 33 cases, we describe the Ukrainian early experience of the management of gunshot wounds to the knee joint with three clinical case studies as representative examples.


  • Open Access

    Modern technologies for replacement of cartilage defects

    by O.A. Buryanov, V.S. Chornyi, M.O. Bazarov, A.о. Mohilnytskyy, V.і. Hutsailiuk, А.P. Kusyak, K.V. Honchar

    Background. The prevalence of joint diseases affecting cartilage tissue and all components of the joint due to trauma and degenerative-dystrophic conditions has notably risen in recent years. Despite an extensive body of research, addressing large bone and cartilage defects remains a significant clinical challenge. This reality underscores the imperative to innovate treatment methods and enhance existing approaches. In this review, we will examine and analyse contemporary materials and techniques for replacing cartilage defects, including hydrogels, nanofibers, 3D membranes, and BioCartilage. Additionally, it explores key aspects of orthobiology, specifically the utilisation of mesenchymal stem cells and exosomes. The article also considers instances of employing modern methods to replace cartilage defects in both experimental and clinical studies. The purpose was to investigate, analyse, and interpret data on the application of contemporary materials and methods for cartilage defect replacement as described in experimental, clinical, and review studies. Materials and methods. A comprehensive literature search was conducted using terms such as osteochondral defect, BioCartilage, nanofiber, allograft cartilage, mesenchymal stem cell, hydrogel, and nonwoven membranes. The search was conducted on the basis of Google Scholar, CrossRef, PubMed databases for the last 5 years. Logical analysis and evaluation were performed on the results of studies encompassing diverse modern technologies and principles for replacing cartilage tissue defects. Results. Microfracturing and tunneling are quite effective methods in replacing cartilage defects with cartilage-like regenerate. Their effectiveness reduces with increa-sing mechanical and axial loads on the formed regenerate. Experimental studies show that physical properties of hydrogel can be compared to native cartilage tissue. Moreover, hydrogel can be used as a matrix for the delivery of anti-inflammatory and some biological drugs. However, this method needs more specific clinical and experimental studies to be put into practice. The use of exosomes to replace osteochondral defects is a simple method, but rapid degradation limits its effectiveness. Combining exosomes with hydrogel or hyaluronic acid can solve these problems by prolonging their release and degradation, enhancing biological activity and biocompatibility. Bioprinting and nanofiber sponge (3D membrane) have reasonable theoretical and experimental value for replacing cartilage defects and require further clinical studies. Promising methods of cartilage tissue regeneration are the implantation of autologous chondrocytes, the use of ChondroFiller and BioCartilage. For a wider assessment of the results of using these treatment methods, longer clinical studies are needed. ­Conclusions. An analysis of more than 36 literature sources, including review, experimental, and clinical studies, reveals a structured summary of the latest research and developments in cartilage tissue defect repair. There is no universal technology for replacing cartilage defects that would be suitable for all patients. Therefore, this review highlights the advantages of different methods for cartilage defect repair adapted to specific clinical cases. Based on the analysis of literature data regarding the use of implant materials to correct cartilage defects in orthopaedics and traumatology, it can be concluded that the chosen direction of scientific research is relevant and significant. Additionally, certain aspects of the development of this issue can be outlined, and questions requiring further study and resolution can be identified.